Henley Business Angels Members invest in Anya, a HealthTech company empowering women through 24/7 personalised care, marking the network’s second-largest investment to date

Anya, a HealthTech company utilising advanced AI to deliver personalised, 24/7 care to women, empowering them to take control of their health, has received investment from five Henley Business Angels members, contributing towards Anya’s seed round and marking the network’s second-largest investment in a company to date.

Across the world, 2.4 billion people suffer through key life stages without the support they need. From menstrual health, to fertility and pregnancy, to menopause, people feel isolated, overwhelmed by the volume of available information, leading to worry about its reliability and concern about the lack of support available. Current methods employed to solve these issues are insufficient: unreliable, unavailable and unaffordable, and not only does it affect the individuals at the heart of these life stages, but also employers, health services, and society as a whole. 

Anya solves these problems through its 24/7 healthcare and companionship tool. Powered by advanced AI, Anya is available 365 days a year, providing an immediate response. Anya is reliable, with NHS accreditation and clinically proven to support users. Additionally, Anya is affordable, costing significantly less than traditional telehealth services.

The app integrates life-stage support across 4 product pillars and verticals. Users have access to a virtual companion chatbot that leverages 1-2-1 human expert support; personalised content and programmes based on unique health journeys and life stages; 1-2-1 video consultations with leading healthcare specialists; and virtual communities that provide vital peer support, with expert webinars and virtual specialist drop-ins.

Led by Founder, CEO & CTO Dr Chen Davies, Anya’s AI offering has been years in the making, with clinicians and machine learning engineers training the product to deliver evidence-based, deterministic responses with 0% hallucination. The product is clinically safe, with a high confidence score, and only a small percentage of users require a human specialist for more in-depth support. The strength of the technology is demonstrated through its wide adoption in the NHS, covering over 7m UK population, and Anya is now ready to launch into the private sector.

Anya is the Tussell Tech 200 fastest-growing technology suppliers in the UK public sector, ranking #10 in HealthTech. 1 in 9 birthing families have access to Anya support via the NHS maternity care pathway. The investment raised from this funding round will be focused primarily on growing the team and expanding the product offering to broader women’s health (including menopause, fertility, and menstrual health) and expanding into the private sector market for corporates as an employee benefit solution and insurers as a value-added women’s health solution.